網宿科技(300017.SZ):TrueBinding的主要產品為針對阿爾茲海默症的藥物TB006,目前已完成臨牀I期及臨牀IIA實驗,實驗結果符合預期
格隆匯5月6日丨網宿科技(300017.SZ)於2023年5月5日下午15:00-17:00召開業績説明會,在問答環節中,就“子公司投資的美國生物醫藥公司什麼情況,方便詳細介紹下進展,收益。”,公司回覆稱,,TrueBinding是一家專注臨牀醫學的生物製藥公司,具備自主完成藥物靶點發現、抗體生成工程、抗體藥物製造的能力。目前,TrueBinding的主要產品為針對阿爾茲海默症的藥物TB006,目前TB006已完成了臨牀I期及臨牀IIA實驗,實驗結果符合預期;該藥物後續尚需完成臨牀IIB實驗,臨牀III期實驗及新藥上市申請等階段。關於該投資的進展,請您關注公司後續公吿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.